AMAO76 Alleviates the Pressure for Amakem Therapeutics
Jack Elands, CEO for Amakem, talks about his company’s focus on a localized drug action platform, and details the company’s feature glaucoma product to lower intraocular pressure designated, AMAO76 rokinase inhibitor.
Presenter:
Jack Elands
Dr. Jack Elands has been the CEO of Amakem since its inception. Before, Jack was CBO of Silicos, an informatics based biotechnology company, CEO of Vitec, a specialty biotech company focused on antimicrobial products and VP of Business Development at Sidec, a biotech focused on developing protein based drugs.